Essential Role Of Sympathetic Endothelin A Receptors For Adverse Cardiac Remodeling

In preclinical studies, endothelin receptor A (ETA) antagonists (ET(A)i) attenuated the progression of heart failure (HF). However, clinical HF trials failed to demonstrate beneficial effects of ET(A)i. These conflicting data may be explained by the possibility that established HF drugs such as adrenergic receptor blockers interfered with the mechanism of ETAi action in clinical trials. Here we report that mice lacking ETA only in sympathetic neurons (SN-KO) showed less adverse structural remodeling and cardiac dysfunction in response to pathological pressure overload induced by transverse aortic constriction (TAC). In contrast, mice lacking ETA only in cardiomyocytes (CM-KO) were not protected. TAC led to a disturbed sympathetic nerve function as measured by cardiac norepinephrine (NE) tissue levels and [I-124]-metaiodobenzylguanidine-PET, which was prevented in SN-KO. In a rat model of HF, ET(A)i improved cardiac and sympathetic nerve function. In cocultures of cardiomyocytes (CMs) and sympathetic neurons (SNs), endothelin-1 (ET1) led to a massive NE release and exaggerated CM hypertrophy compared with CM monocultures. ETA-deficient CMs gained a hypertrophic response through wild-type SNs, but ETA-deficient SNs failed to mediate exaggerated CM hypertrophy. Furthermore, ET1 mediated its effects indirectly via NE in CM-SN cocultures through adrenergic receptors and histone deacetylases, resulting in activation of the prohypertrophic transcription factor myocyte enhancer factor 2. In conclusion, sympathetic ETA amplifies ET1 effects on CMs through adrenergic signaling pathways. Thus, antiadrenergic therapies may blunt potentially beneficial effects of ET(A)i. Taken together, this may indicate that patients with beta blocker intolerance or disturbed sympathetic nerve function could be evaluated for a potential benefit from ET(A)i.